Jasvinder A Singh1,2. 1. Medicine Service, Birmingham VA Medical Center. 2. Department of Medicine at School of Medicine, and Division of Epidemiology at School of Public Health, University of Alabama, Birmingham, AL, USA.
Abstract
OBJECTIVE: The aim was to examine the views of health-care providers regarding disease modification in gout, with the potential to derive a provisional set of domains for disease modification in gout. METHODS: A qualitative nominal group study was performed with 20 gout experts (15 expert/expert panel members of the 2012 and/or 2020 ACR gout guidelines and/or 2015 ACR/EULAR gout classification criteria) about what constitutes disease modification in gout: 'What sorts of things do you think constitute a change in the course of disease in gout? (positive); what are all the ways in which gout as a disease can be modified?' RESULTS: Decrease in gout flares was rated number one rank in all six nominal groups as indicative of disease modification in gout, followed by serum urate lowering, which was rated number one rank in one of the six nominal groups (tied score with flares in one nominal group). Other components of gout disease modification were to improve quality of life/productivity; restore function; reduce/eliminate pain; reduce tophi burden; and joint preservation or resolution of joint damage. Potential additional components that were not ranked in the top three votes within each nominal group were: decreasing health-care cost/utilization; reducing cardiovascular/renal morbidity/mortality; and stopping formation of urate crystals. CONCLUSION: This qualitative study provides a provisional set of domains for disease modification in gout. Future studies for the development of thresholds for disease modification domains and wider consensus on this definition are needed. Published by Oxford University Press on behalf of the British Society for Rheumatology 2022. This work is written by a US Government employee and is in the public domain in the US.
OBJECTIVE: The aim was to examine the views of health-care providers regarding disease modification in gout, with the potential to derive a provisional set of domains for disease modification in gout. METHODS: A qualitative nominal group study was performed with 20 gout experts (15 expert/expert panel members of the 2012 and/or 2020 ACR gout guidelines and/or 2015 ACR/EULAR gout classification criteria) about what constitutes disease modification in gout: 'What sorts of things do you think constitute a change in the course of disease in gout? (positive); what are all the ways in which gout as a disease can be modified?' RESULTS: Decrease in gout flares was rated number one rank in all six nominal groups as indicative of disease modification in gout, followed by serum urate lowering, which was rated number one rank in one of the six nominal groups (tied score with flares in one nominal group). Other components of gout disease modification were to improve quality of life/productivity; restore function; reduce/eliminate pain; reduce tophi burden; and joint preservation or resolution of joint damage. Potential additional components that were not ranked in the top three votes within each nominal group were: decreasing health-care cost/utilization; reducing cardiovascular/renal morbidity/mortality; and stopping formation of urate crystals. CONCLUSION: This qualitative study provides a provisional set of domains for disease modification in gout. Future studies for the development of thresholds for disease modification domains and wider consensus on this definition are needed. Published by Oxford University Press on behalf of the British Society for Rheumatology 2022. This work is written by a US Government employee and is in the public domain in the US.
Authors: H Ralph Schumacher; Lawrence N Edwards; Fernando Perez-Ruiz; Michael Becker; Lan X Chen; Daniel E Furst; Nancy Joseph-Ridge; Naomi Schlesinger; Zeb Horowitz; Kenneth Saag; Judith A Boice; Hisashi Yamanaka Journal: J Rheumatol Date: 2005-12 Impact factor: 4.666
Authors: Josef S Smolen; Robert B M Landewé; Johannes W J Bijlsma; Gerd R Burmester; Maxime Dougados; Andreas Kerschbaumer; Iain B McInnes; Alexandre Sepriano; Ronald F van Vollenhoven; Maarten de Wit; Daniel Aletaha; Martin Aringer; John Askling; Alejandro Balsa; Maarten Boers; Alfons A den Broeder; Maya H Buch; Frank Buttgereit; Roberto Caporali; Mario Humberto Cardiel; Diederik De Cock; Catalin Codreanu; Maurizio Cutolo; Christopher John Edwards; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Laure Gossec; Jacques-Eric Gottenberg; Merete Lund Hetland; Tom W J Huizinga; Marios Koloumas; Zhanguo Li; Xavier Mariette; Ulf Müller-Ladner; Eduardo F Mysler; Jose A P da Silva; Gyula Poór; Janet E Pope; Andrea Rubbert-Roth; Adeline Ruyssen-Witrand; Kenneth G Saag; Anja Strangfeld; Tsutomu Takeuchi; Marieke Voshaar; René Westhovens; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2020-01-22 Impact factor: 19.103
Authors: Wendy K Jefferson; Christie Zunker; Jennifer C Feucht; Stephanie L Fitzpatrick; Lori F Greene; Richard M Shewchuk; Monica L Baskin; Norman W Walton; Beatrice Phillips; Jamy D Ard Journal: Eval Program Plann Date: 2009-12-05
Authors: Nicola Dalbeth; Christopher Frampton; Maple Fung; Scott Baumgartner; Savvas Nicolaou; Hyon K Choi Journal: Arthritis Res Ther Date: 2019-06-21 Impact factor: 5.156
Authors: Clyde T Matava; Pete G Kovatsis; Jennifer K Lee; Pilar Castro; Simon Denning; Julie Yu; Raymond Park; Justin L Lockman; Britta Von Ungern-Sternberg; Stefano Sabato; Lisa K Lee; Ihab Ayad; Sam Mireles; David Lardner; Simon Whyte; Judit Szolnoki; Narasimhan Jagannathan; Nicole Thompson; Mary Lyn Stein; Nicholas Dalesio; Robert Greenberg; John McCloskey; James Peyton; Faye Evans; Bishr Haydar; Paul Reynolds; Franklin Chiao; Brad Taicher; Thomas Templeton; Tarun Bhalla; Vidya T Raman; Annery Garcia-Marcinkiewicz; Jorge Gálvez; Jonathan Tan; Mohamed Rehman; Christy Crockett; Patrick Olomu; Peter Szmuk; Chris Glover; Maria Matuszczak; Ignacio Galvez; Agnes Hunyady; David Polaner; Cheryl Gooden; Grace Hsu; Harshad Gumaney; Caroline Pérez-Pradilla; Edgar E Kiss; Mary C Theroux; Jennifer Lau; Saeedah Asaf; Pablo Ingelmo; Thomas Engelhardt; Mónica Hervías; Eric Greenwood; Luv Javia; Nicola Disma; Myron Yaster; John E Fiadjoe Journal: Anesth Analg Date: 2020-07 Impact factor: 5.108